tbuckley/cabot-search huggingface dataset:
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Authors: Brian M. Slomovitz, David Cibula, Weiguo Lv, Fırat Ortaç, Sakari Hietanen, Floor Backes, Akira Kikuchi, Domenica Lorusso, Anna Dańska-Bidzińska, Vanessa Samouëlian, Maria-Pilar Barretina-Ginesta, Christof Vulsteke, Chyong-Huey Lai, Bhavana Pothuri, Yu Zhang, Manuel Magallanes-Maciel, Amnon Amit, Valentina Guarneri, Flora Zagouri, Maria Bell, Julia Welz, Gemma Eminowicz, Martin Hruda, Lyndsay J. Willmott, Jasmine Lichfield, Wei Wang, Robert Orlowski, Gursel Aktan, Laurence Gladieff, Toon Van Gorp
Journal: Journal of Clinical Oncology (2024)

Mismatch repair-deficient (dMMR) endometrial cancer (EC) is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options in the adjuvant setting. We report protocol-prespecified subgroup analysis of patients with dMMR tumors from the phase III ENGOT-en11/GOG-3053/KEYNOTE-B21 study (ClinicalTrials.gov identifier: NCT04634877 ) in newly diagnosed, high-risk EC after surgery with curative intent. Patients were randomly assigned to pembrolizumab 200 mg or placebo (six cycles) plus carboplatin-paclitaxel (four to six cycles) once every 3 weeks, then pembrolizumab 400 mg or placebo once every 6 weeks (six cycles), respectively. MMR status was a stratification factor. Patients received radiotherapy at investigator discretion. Investigator-assessed disease-free survival (DFS) was a primary end point. No formal hypothesis testing was performed for subgroup analysis. In the intention-to-treat population, 141 patients in the pembrolizumab arm and 140 in the placebo arm had dMMR tumors. At this interim analysis, hazard ratio for DFS favored pembrolizumab (0.31 [95% CI, 0.14 to 0.69]); median DFS was not reached in either group. Two-year DFS rates were 92.4% (95% CI, 84.4 to 96.4) and 80.2% (95% CI, 70.8 to 86.9), respectively. No new safety signals occurred. Longer-term follow-up of outcomes will be evaluated at final analysis. Preplanned subgroup analysis on the basis of the study's stratification factors suggests that pembrolizumab plus chemotherapy improves DFS and is clinically relevant for patients with dMMR tumors in the curative-intent setting.
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
Authors: M Martín, S R Stecklein, O Gluz, G Villacampa, M Monte-Millán, U Nitz, S Cobo, M Christgen, F Brasó-Maristany, E L Álvarez, I Echavarría, B Conte, S Kuemmel, C Bueno-Muiño, Y Jerez, R Kates, M Cebollero, C Kolberg-Liedtke, O Bueno, J Á García-Saenz, F Moreno, E-M Grischke, H Forstbauer, M Braun, M Warm, J Hackmann, C Uleer, B Aktas, C Schumacher, R Wuerstleins, M Graeser, C Zu Eulenburg, H H Kreipe, H Gómez, T Massarrah, B Herrero, L Paré, U Bohn, S López-Tarruella, A Vivancos, E Sanfeliu, J S Parker, C M Perou, P Villagrasa, A Prat, P Sharma, N Harbeck
Journal: Annals of Oncology (2024)
Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines
Authors: Anthony M Marchese, Louis Fries, Hadi Beyhaghi, Muruga Vadivale, Mingzhu Zhu, Shane Cloney-Clark, Joyce S Plested, Amy W Chung, Lisa M Dunkle, Raj Kalkeri
Journal: Journal of Infection (2024)
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
Authors: Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M. Morán-Segura, Jonathan V. Nguyen, Lazaros Lekakis, Sebastian Fernandez-Pol, Annie N. Samraj, Kikkeri N. Naresh, Mariola Vazquez-Martinez, Rachid C. Baz, Jay Y. Spiegel, Lekha Mikkilineni, John M. Gubatan, Surbhi Sidana, Andre de Menezes Silva Corraes, Nilesh M. Kalariya, Krina K. Patel, Kevin G. Shim, Rafael Fonseca, Christopher Ferreri, Peter M. Voorhees, Shambavi Richard, Cesar Rodriguez Valdes, None Sireesha Asoori, Jeffrey L. Wolf, Andrew J. Cowan, Douglas W. Sborov, Frederick L. Locke, Yi Lin, Yinghong Wang, Doris K. Hansen
Journal: Blood Cancer Journal (2024)

We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22-210 days) after CAR-T therapy and a median of 85 days after cytokine release syndrome resolution. Gut biopsies uniformly demonstrated inflammation, including intra-epithelial lymphocytosis and villous blunting. In one case where CAR-specific immunofluorescence stains were available, CAR T-cell presence was confirmed within the lamina propria. Systemic corticosteroids were initiated in 10 patients (71%) a median of 25.5 days following symptom onset, with symptom improvement in 40%. Subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. Five patients (36%) have died from bowel perforation or treatment-emergent sepsis. In conclusion, IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy typically beginning 1-3 months after infusion. Thorough diagnostic workup is essential, including evaluation for potential T-cell malignancies. The early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.
High-fat diet-induced L-saccharopine accumulation inhibits estradiol synthesis and damages oocyte quality by disturbing mitochondrial homeostasis
Authors: Jingyi Wen, Yanzhi Feng, Liru Xue, Suzhen Yuan, Qian Chen, Aiyue Luo, Shixuan Wang, Jinjin Zhang
Journal: Gut Microbes (2024)

High-fat diet (HFD) has been linked to female infertility. However, the specific age at which HFD impacts ovarian function and the underlying mechanisms remain poorly understood. Here, we administered a HFD to female mice at various developmental stages: pre-puberty (4 weeks old), post-puberty (6 weeks old), young adult (9 weeks old), and middle age (32 weeks old). Our observations indicated that ovarian function was most significantly compromised when HFD was initiated at post-puberty. Consequently, post-puberty mice were chosen for further investigation. Through transplantation of fecal bacteria from the HFD mice to the mice on a normal diet, we confirmed that gut microbiota dysbiosis contributed to HFD-induced deteriorated fertility and disrupted estradiol synthesis. Utilizing untargeted and targeted metabolomics analyses, we identified L-saccharopine as a key metabolite, which was enriched in the feces, serum, and ovaries of HFD and HFD-FMT mice. Subsequent
Controlled infection with cryopreserved human hookworm induces CTLA-4 expression on Tregs and upregulates tryptophan metabolism
Authors: Francesco Vacca, Thomas C. Mules, Mali Camberis, Brittany Lavender, Sophia-Louise Noble, Alissa Cait, Kate Maclean, John Mamum, Bibek Yumnam, Tama Te Kawa, Laura Ferrer-Font, Jeffry S. Tang, Olivier Gasser, Graham Le Gros, Stephen Inns
Journal: Gut Microbes (2024)

Infecting humans with controlled doses of helminths, such as human hookworm (termed hookworm therapy), is proposed to prevent or treat various intestinal and extraintestinal diseases. However, full-scale clinical trials examining hookworm therapy are limited by the inability to scale-up the production of hookworm larvae to infect sufficient numbers of patients. With the aim of overcoming this challenge, this study infected four healthy individuals with hookworm larvae that had been reanimated from cryopreserved eggs to examine their viability and immunogenicity. We demonstrate that reanimated cryopreserved hookworm larvae establish a viable hookworm infection and elicit a similar immune response to larvae cultured from fresh stool. Furthermore, a refined understanding of the therapeutic mechanisms of hookworm is imperative to determine which diseases to target with hookworm therapy. To investigate potential therapeutic mechanisms, this study assessed changes in the immune cells, microbiome, and plasma metabolome in the four healthy individuals infected with cryopreserved hookworm larvae and another nine individuals infected with larvae cultured from freshly obtained stool. We identified potential immunoregulatory mechanisms by which hookworm may provide a beneficial effect on its host, including increased expression of CTLA-4 on regulatory T cells (Tregs) and upregulation of tryptophan metabolism. Furthermore, we found that a participant's baseline microbiome predicted the severity of symptoms and intestinal inflammation experienced during a controlled hookworm infection. In summary, our findings demonstrate the feasibility of full-scale clinical trials examining hookworm therapy by minimizing the reliance on human donors and optimizing the culturing process, thereby enabling viable hookworm larvae to be mass-produced and enabling on-demand inoculation of patients. Furthermore, this study provides insights into the complex interactions between helminths and their host, which could inform the development of novel therapeutic strategies.
EP.06G.18 Lung Cancer with Pleural Dissemination is Potentially a Non-Shedding Tumor
Authors: H. Hong, J.-T. Zhang, Y. Zhang, M. Song, X. Gao, H.-J. Li, S.-R. Cui, S. Dong, Y.-L. Wu, W.-Z. Zhong
Journal: Journal of Thoracic Oncology (2024)
EP.14B.03 Predictive Value of Neutrophil-to-Lymphocyte Ratio (NLR) and Absolute Lymphocyte Count (ALC) In Thymic Epithelial Tumors
Authors: N. Choradia, L. DaSilva, K. Dodd, M. McAdams, S. Swift, C. Feierabend, A. Sivapiromrat, S. Sansone, C. Zhao, R.N. Donahue, J. Schlom, J.L. Gulley, A. Rajan, E. Szabo
Journal: Journal of Thoracic Oncology (2024)
EP.14C.10 Clinical and Pathoanatomical Characteristics of Rare Pulmonary Neuroendocrine Tumors in Greek Population
Authors: T. Sen, G. Evangelou, A. Sofianidi, P. Kelidi, A. Papadopoulou, A. Konstantinidou, N. Syrigos, K. Syrigos
Journal: Journal of Thoracic Oncology (2024)
P1.13B.01 Lurbinectedin vs. Platinum Rechallenge in Extensive Stage Small Cell Lung Cancer after Platinum Doublet, A Multicenter Retrospective Study
Authors: M. Libre, A. Barsouk, M. Lu, S. Lessans, O. Elghawy, C. Yu, K. Goel, J. Wu, S. Bhatia, A. Cass, M. Marmarelis, W. Iams
Journal: Journal of Thoracic Oncology (2024)
EP.14A.01 Prospective Analysis of Patterns of Care and Clinical Outcomes for People Diagnosed with Mesothelioma in Australia
Authors: S. Harden, D. Samankula, S. Tissera, M. Lloyd, V. Hamilton, B. Healey, K. Healey, E. MacFarlane, K. Walker-Bone, S. Muruganandan, B. Dunne, T. John, F. Brims, R. Stirling, J. Zalcberg
Journal: Journal of Thoracic Oncology (2024)
EP.11A.10 Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Authors: G. Suay, A. Ortiz-Gracia, C. Rodrigo, J. Linares, J.-C. Garcia-Cañaveras, A. Armero, F. Aparisi, A. Lahoz, O. Juan-Vidal
Journal: Journal of Thoracic Oncology (2024)
EP.17A.07 ROSETTA-LUNG: MultidisciplinaRy Oncology StratEgies for Team-Based Treatment ConcordAnce in Lung Cancer Diagnosis and Treatment Decisions
Authors: M.H. Kristensen, M. Sandelin, M. Paz Saavedra Valenzuela, L. Thamlikitkul, A. van Vliet, W. Brueckl, T.R. Rasmussen
Journal: Journal of Thoracic Oncology (2024)
EP.12B.02 Real-World Treatment Patterns and Effectiveness in Patients with ALK+ Advanced NSCLC Treated with 1L ALK TKIs
Authors: Y. CHEN, H.M. Lin, Y. Wan, Y. Yin, Y. Wu, L. Hernandez, C. Danes, E.N. Churchill, A. Dimou
Journal: Journal of Thoracic Oncology (2024)
EP.16B.01 UK and US Patient Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitors Treatments
Authors: K.W. Culver, D. Montague, H. Le, J. Coulter, J.C. Cappelleri, H. Lu, M. Quaife, K. Meginnis, G. Fernandez, S. Vaghela, N. Rifi, T. Stinchcombe
Journal: Journal of Thoracic Oncology (2024)
EP.12A.36 Early Experience with the FLAURA2 Regimen in Patients with NSCLC and EGFR Mutations in Latin America
Authors: J. Zuluaga, A.F. Cardona, V.C.C.d. Lima, O. Arrieta, L. Rojas, J.D. Flórez, S. Mejía, H. Freitas, L. Corrales, C. Martín, L. Mas, R. Motta, L. Viola, S. Martínez, C. Carvajal, N. Wagner-Gutierrez, N. Sánchez, L. Raez, L.E. Pino, C. Rolfo
Journal: Journal of Thoracic Oncology (2024)
EP.07C.15 Neoadjuvant Immuno-Chemotherapy in Resectable Non-Small Cell Lung Cancer - A Retrospective Cohort Study
Authors: S. Verma, M.D. Vincent, M. Black, R. Nayak, M. Cecchini, R. Malthaner, J. Raphael, R. Inculet, D. Fortin, P. Blanchette, S. Kuruvilla, M. Qiabi, J. Younus, D.A. Breadner
Journal: Journal of Thoracic Oncology (2024)
EP.08D.17 Long-Term Survival Outcomes of Surgery after Neoadjuvant TKI for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutations
Authors: M. Aoki, G. Kamimura, S. Morizono, T. Tokunaga, A.H. Takeda, K. Maeda, T. Nagata, K. Ueda
Journal: Journal of Thoracic Oncology (2024)
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study
Authors: R. Tagawa, S. Takemoto, H. Gyotoku, H. Taniguchi, M. Matsuo, H. Tomono, K. Akagi, S. Ono, F. Hayashi, T. Fukuda, H. Mukae
Journal: Journal of Thoracic Oncology (2024)
EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses
Authors: I. Borchardt, G. Farias, G. Fraga, C. Augusto, S. Chek, J. Janoni, J. Oliveira, J. Lattanzi, A. Barcellos, V. Figueiredo, C. Alves, F. Telles, F. Dias, P. De Marchi, T. Montella, W. Peres, A. Melo, C.G. Ferreira
Journal: Journal of Thoracic Oncology (2024)
EP.12A.05 Evaluation of the Role of VAF/cellularity as Proxy of Gene Aberration in EGFR Mutated Advanced NSCLC During Osimertinib
Authors: M. Brambilla, D. Lorenzini, G. Nardo, M. Occhipinti, G. Mazzoli, T. Beninato, L. Mazzeo, R. Leporati, S. Manglaviti, D. Miliziano, G. Di Liberti, C. Giani, A.D. Dumitrascu, T. Serra Cassano, A. Prelaj, C. Proto, M. Ganzinelli, F. de Braud, G. Lo Russo
Journal: Journal of Thoracic Oncology (2024)
P1.13A.12 Exposure-Response Analyses to Support Ph3 Dose Selection for I-Dxd (Ifinatamab Deruxtecan) in Extensive Stage SCLC Patients
Authors: N.M. Midde, S. Hennig, B.P. Tran, M. Qian, M. Tang, J. Singh, S.S. Vaidya, Y. Lau
Journal: Journal of Thoracic Oncology (2024)
EP.12A.15 ACTN4 as a Predictive Biomarker for Osimertinib Efficacy in EGFR Mutant Non-Small Cell Lung Cancer
Authors: T. Tozuka, R. Noro, Y. Naito, N. Miura, S. Kunugi, K. Honda, M. Seike
Journal: Journal of Thoracic Oncology (2024)
EP.14C.07 Hyperossosis of the Right 10th Rib the Osteochondral Part that Compresses the Dexter Lobe of the Liver
Authors: F. Gradica, A. Cani, L. Lisha, I. Peposhi, F. Kokici, A. Leka, D. Xhemalaj, M. Rama, S. Gradica, L.G. Matmuja, F. Hoxha
Journal: Journal of Thoracic Oncology (2024)
EP.07E.01 Intrinsic Impacts of the Expression of PD-L1 On Postoperative Recurrence in EGFR-Mutated Lung Adenocarcinoma
Authors: A. Ito, S. Kano, T. Tarukawa, Y. Suzuki, T. Sakaguchi, K. Ito, Y. Nishii, O. Taguchi, H. Yasui, O. Hataji
Journal: Journal of Thoracic Oncology (2024)
EP.13C.06 Feasibility of Hippocampal Sparing Radiotherapy in Lung Cancer Patients Requiring Cranial Irradiation (HSWBRT-LC)
Authors: D. Khosla, T. Dey, R. Kapoor, N. Singh, G. Trivedi, V. Kataria, A.K. Singla, R. Madan, S. Goyal, A.S. Oinam, A. Sharma
Journal: Journal of Thoracic Oncology (2024)
EP.07G.01 Computed Tomography Features of Pathological Stage IA Lung Adenocarcinoma Showing Spread Through Air Spaces.
Authors: T. Saito, Y. Kono, Y. Ueno, N. Maru, T. Utsumi, H. Matsui, Y. Taniguchi, H. Hino, K. Tsuta, O. Honda, T. Murakawa
Journal: Journal of Thoracic Oncology (2024)
EP.11A.20 Incidence and Outcomes of Adrenal Oligoprogression in Metastatic Lung Cancer During Immunotherapy
Authors: B.V. Miyamura, F.C. Maluf, F.M. Silva, G.M. Andriatte, I.Q. Castro, L.S. Bugalho, L.O.M. Koch, V.A.R. Sousa, O. Smaletz, G. Schvartsman
Journal: Journal of Thoracic Oncology (2024)
EP.17F.06 Enhancing Lung Cancer Care and Patient Access at Regional Level - The Impact of Inter-Hospital Remote Multidisciplinary Team Consultations
Authors: Y. Li, L. Tu, F. Yu, G.-W. Che, B.-C. Yin, M. Li, Y.-C. Zhang, J.-T. Zhang, P.J.-Y. Cui
Journal: Journal of Thoracic Oncology (2024)
EP.12C.03 Toxicities Associated with Immune Checkpoint Inhibitors Followed by KRAS G12C Inhibitors in Patients with Metastatic NSCLC
Authors: S. Kagalwalla, M. Patel, N. Fujioka, B. Manning, R. Kratzke, A.A. Kulkarni
Journal: Journal of Thoracic Oncology (2024)
EP.15A.02 Prospective Evaluation of A Single-Day Multidisciplinary Clinic for Patients with Locally Advanced Non-Small Cell Lung Cancer
Authors: D.L. Billing, J.E. Chaft, D.R. Jones, R. Daly, A.J. Schoenfeld, B.A. Mueller, I. Preeshagul, B.J. Park, P. Iyengar, D.R. Gomez
Journal: Journal of Thoracic Oncology (2024)
EP.07D.03 A Quality Improvement Initiative to Address Biomarker Testing and Quality of Care Delivery for Early-Stage NSCLC at 3 Cancer Centers in the US
Authors: M. Smeltzer, J. Kim, B. Alvarez, M. Shiller, E. Plotkin, A. Lile, R. Emara, J.L. Studts, P. Lee
Journal: Journal of Thoracic Oncology (2024)
EP.11A.29 C-Reactive Protein's Impact on Immune Adverse Events in Non Small Cell Lung Cancer Patients Undergoing Immunotherapy: Meta-Analysis
Authors: S. Saowapa, C. Wannaphut, M. Tanariyakul, N. Polpichai, P. Wattanachayakul, P. Siladech, T. Suenghataiphorn, H.G. Pleitez, L. Tijani
Journal: Journal of Thoracic Oncology (2024)
EP.11A.25 Consensus on Maintenance Therapy after a First-Line Pembrolizumab-Containing Regimen in Advanced/metastatic NSCLC
Authors: U. Tapan, M. Shah, K.F. Bell, A. Liao, H. Yang, S. Lee, L. Korrapati, N. Reinmuth
Journal: Journal of Thoracic Oncology (2024)
EP.08F.14 Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective Real-World Study
Authors: L. Ljubicic, L. Bitar, F. Seiwerth, A. Bacelic-Gabelica, D. Srdic, S. Badovinac, S. Plestina, M. Korsic, T. Pavic, M. Samarzija, M. Jakopovic
Journal: Journal of Thoracic Oncology (2024)
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib
Authors: F. Zwierenga, B. Muntinghe-Wagenaar, P. Rozendal, P. van der Leest, E. Schuuring, A.J. van der Wekken
Journal: Journal of Thoracic Oncology (2024)
EP.08D.08 Aumolertinib as Neoadjuvant Therapy for EGFR M+ NSCLC: A Subcohort Analysis of PURPOSE Trial Data Updated
Authors: Y.Y. Wang, Z.T. Gu, F.C. Bao, T. Mao, C.Y. Ji, J. Wang, Y.R. Cai, B. Li, W.T. Fang
Journal: Journal of Thoracic Oncology (2024)
EP.07A.10 Concordance Between Lymph Node Station Examination Reported on a Checklist and the Final Pathology Report after Curative Lung Cancer Resection
Authors: M. Ray, S. Ely, O. Akinbobola, C. Fehnel, A. Saulsberry, K. Dortch, M. Smeltzer, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2024)
Vitamin B<sub>12</sub> protects necrosis of acinar cells in pancreatic tissues with acute pancreatitis
Authors: Yulin Chen, Xue Li, Ran Lu, Yinchun Lv, Yongzi Wu, Junman Ye, Jin Zhao, Li Li, Qiaorong Huang, Wentong Meng, Feiwu Long, Wei Huang, Qing Xia, Jianbo Yu, Chuanwen Fan, Xianming Mo
Journal: MedComm (2024)

Pharmacological agents regarding the most optimal treatments of acute pancreatitis remain. One-carbon metabolism nutrients as therapeutic agents in many diseases might be involved in acute pancreatitis. The roles are acquired exploration in acute pancreatitis. We utilized Mendelian randomization to assess the causal impact of folate, homocysteine, and vitamin B
EP.03F.03 Orally Bioavailable Cyclin A/B Rxl Macrocycle has Antitumor Effect in SCLC &amp; NSCLC Cell Line Derived (CDX) &amp; Patient Derived Xenograft (PDX) Models
Authors: B. Levin, L.-F. Liu, F. Hamkins-Indik, R. Odeh, C.E. Gleason, P.D. Garcia, D.J. Earp, M.C. Cox, E.W. Wang
Journal: Journal of Thoracic Oncology (2024)
EP.03G.01 Comparison of Tumor Immune Microenvironments Between Primary and Metastatic Sites in Non-Small Cell Lung Cancer
Authors: K. Sankar, J. Mercer, E. Jaeger, J. Godden, E. Williams, M. Thompson, S. Patel, K. Reckamp, F. Weinberg
Journal: Journal of Thoracic Oncology (2024)
EP.03B.01 The Genomic Scarring Score as a Biomarker for the Use of PARP Inhibitors in Early-Stage Non-Small Cell Lung Cancer
Authors: K. Tsilingiri, A. Chalari, G. Christopoulou, A. Voutsina, I. Vatsellas, T. Loupis, D. Vrachnos, K. Potaris, I. Vamvakaris, G. Zachou, V. Georgoulias, P. Constantoulakis, A. Kotsakis, A. Klinakis
Journal: Journal of Thoracic Oncology (2024)
Hypoxia and aging: molecular mechanisms, diseases, and therapeutic targets
Authors: Ayesha Nisar, Sawar Khan, Wen Li, Li Hu, Priyadarshani Nadeeshika Samarawickrama, Naheemat Modupeola Gold, Meiting Zi, Sardar Azhar Mehmood, Jiarong Miao, Yonghan He
Journal: MedComm (2024)

Abstract Aging is a complex biological process characterized by the gradual decline of cellular functions, increased susceptibility to diseases, and impaired stress responses. Hypoxia, defined as reduced oxygen availability, is a critical factor that influences aging through molecular pathways involving hypoxia‐inducible factors (HIFs), oxidative stress, inflammation, and epigenetic modifications. This review explores the interconnected roles of hypoxia in aging, highlighting how hypoxic conditions exacerbate cellular damage, promote senescence, and contribute to age‐related pathologies, including cardiovascular diseases, neurodegenerative disorders, cancer, metabolic dysfunctions, and pulmonary conditions. By examining the molecular mechanisms linking hypoxia to aging, we identify key pathways that serve as potential therapeutic targets. Emerging interventions such as HIF modulators, antioxidants, senolytics, and lifestyle modifications hold promise in mitigating the adverse effects of hypoxia on aging tissues. However, challenges such as the heterogeneity of aging, lack of reliable biomarkers, and safety concerns regarding hypoxia‐targeted therapies remain. This review emphasizes the need for personalized approaches and advanced technologies to develop effective antiaging interventions. By integrating current knowledge, this review provides a comprehensive framework that underscores the importance of targeting hypoxia‐induced pathways to enhance healthy aging and reduce the burden of age‐related diseases.
EP.05A.01 Efficacy and Safety of Midazolam with Fentanyl for Sedation During EBUS-TBNA: A Randomized, Double-Blind, Phase III Study
Authors: J. Yamada, D. Hazama, T. Fukui, A. Yatani, M. Okamoto, S. Fujimoto, R. Yoshimura, M. Takayasu, N. Takata, H. Sato, C. Mimura, K. Furukawa, N. Katsurada, M. Yamamoto, M. Tachihara
Journal: Journal of Thoracic Oncology (2024)
EP.04A.12 Exploring Rural Appalachian Community Perceptions and Practices on Health and Lung Cancer to Inform Screening Interventions
Authors: M.R. gieske, D. Avery, R. Bell, C. Crabtree-Ide, J. Gruenberg, M. Futrell, A. Harvey, M. Kisiel, L. McCauley-Hixenbaugh, S. Phillips, E. Plotkin, M. Reid, A. Lile
Journal: Journal of Thoracic Oncology (2024)
EP.07C.03 Oncological Outcomes after Lobe-Specific Mediastinal Lymph Node Dissection in Thoracoscopic Right Upper Lobectomy for Clinical N0 NSCLC
Authors: M. Mun, M. Nakao, Y. Matsuura, J. Ichinose, A. Suzuki
Journal: Journal of Thoracic Oncology (2024)
EP.08F.11 Development of Clinical Prediction Model Using Digital Device for ILD in the Stage III NSCLC Patients Treated with Durvalumab
Authors: H. Kenmotsu, S. Ikeda, Y. Sato, C. Iwao, M. Ogi, T. Hirai, R. Koto, H. Kitagawa, N. Yamamoto
Journal: Journal of Thoracic Oncology (2024)
EP.12B.09 Real-World Efficacy and Toxicity Comparison Between the RET Inhibitors (RETi) Pralsetinib and Selpercatinib in Patients with Stage IV NSCLC
Authors: G. Sacchi de Camargo Correia, S. Li, Y. Loy, Y. Zhao, V. Ernani, K. Parikh, A. Dimou, R. Manochakian
Journal: Journal of Thoracic Oncology (2024)